Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.

A study questioned the cost-effectiveness of the test in clinically low-risk women, but the firm stressed that a wealth of evidence continues to support its use under current guidelines.

The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.

Onkos Molecular Diagnostics is looking for a US partner to commercialize its 11 miRNA-based mir-THYpe test, which it believes offers advantages over tests on the market.

Last month, the company announced two transactions that it said would enable it to regain compliance with the Nasdaq's listing requirement.

Last month, the company announced two transactions that it said would enable it to regain compliance with the Nasdaq's listing requirement.

The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.